Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01445951 · ClinicalTrials.gov registry record · Phase 3
Clinical Trial Evaluating Technosphere® Insulin Versus Insulin Aspart in Subjects With Type 1 Diabetes Mellitus Over a 24-week Treatment Period
A Phase 3 study of Type 1 Diabetes Mellitus, sponsored by Mannkind Corporation.
- Completed
- Registry status
- Phase 3
- Development phase
- 518
- Enrollment target
- 20
- Study locations
NCT01445951 is a Phase 3 study of Type 1 Diabetes Mellitus that has completed, run by Mannkind Corporation. The registered enrollment target is 518 participants, above the 135-participant average among 105 other Type 1 Diabetes Mellitus trials with a reported enrollment target (284% higher). The trial reports 20 study locations across 3 states.
The verdict
NCT01445951, a Phase 3 study of Type 1 Diabetes Mellitus, has completed, sponsored by Mannkind Corporation.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 518 participants
- Enrollment target
- 20
- Study locations
Study Summary
Open-label, randomized, forced-titration clinical trial evaluating the efficacy and safety of TI Inhalation Power in combination with a basal insulin versus insulin aspart in combination with a basal insulin
Conditions Studied
Interventions
- DRUG Technosphere® Insulin with MedTone C Inhaler
- DRUG Technosphere ®Insulin with Gen2 Inhaler
- DRUG Insulin Aspart in combination with a basal insulin
Study Locations (20)
California
- - Burlingame
- - Escondido
- - Huntington Beach
- - La Jolla
- - La Mesa
- - Long Beach
- - Los Angeles
- - Los Angeles
- - Los Gatos
- - San Mateo
- - Santa Barbara
- - Tustin
Florida
- - Hialeah
- - Hollywood
- - Miami
- - Miami
- - New Port Richey
- - Palm Harbor
- - West Palm Beach
Colorado
- - Aurora
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 518 participants |
| Start Date | 2011-09 |
| Est. Completion | 2013-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01445951
The ClinicalTrials.gov registry entry for NCT01445951 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 518 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 135-participant average among 105 other Type 1 Diabetes Mellitus trials with a reported enrollment target (284% higher). The listed sponsor is Mannkind Corporation, which has 42 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Type 1 Diabetes Mellitus appearing as the primary indexed condition, and to 3 interventions - of which Technosphere® Insulin with MedTone C Inhaler is the first listed.
NCT01445951 reports 20 study locations spanning 3 distinct geographic areas - top geographies include California, Florida, Colorado.
Frequently Asked Questions
What is clinical trial NCT01445951 about?
NCT01445951 is a clinical study titled "Clinical Trial Evaluating Technosphere® Insulin Versus Insulin Aspart in Subjects With Type 1 Diabetes Mellitus Over a 24-week Treatment Period". Open-label, randomized, forced-titration clinical trial evaluating the efficacy and safety of TI Inhalation Power in combination with a basal insulin versus insulin aspart in combination with a basal insulin
What is the current status of trial NCT01445951?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 518 participants. The study started on 2011-09. Estimated completion is 2013-06.
What conditions does trial NCT01445951 study?
This clinical trial studies the following conditions: Type 1 Diabetes Mellitus.
What interventions are being tested in trial NCT01445951?
The interventions under investigation include: Technosphere® Insulin with MedTone C Inhaler (DRUG), Technosphere ®Insulin with Gen2 Inhaler (DRUG), Insulin Aspart in combination with a basal insulin (DRUG).
Who is sponsoring clinical trial NCT01445951?
This trial is sponsored by Mannkind Corporation, which has 42 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01445951 being conducted?
This trial has 20 study locations across California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Type 1 Diabetes Mellitus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Investigate Efficacy and Safety of Teplizumab Compared With Placebo in Participants 1 to 25 Years of Age With Stage 3 Type 1 Diabetes
RECRUITING · Phase 3
-
Islet Transplantation in Type 1 Diabetic Patients Using the University of Illinois at Chicago (UIC) Protocol
ACTIVE NOT RECRUITING · Phase 3
-
A Phase III Study to Investigate if the Study Drug Diamyd Can Preserve Insulin Production and Improve Glycemic Control in Patients Newly Diagnosed With Type 1 Diabetes
ACTIVE NOT RECRUITING · Phase 3
-
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 1 Diabetes Mellitus
COMPLETED · Phase 3
-
Pediatric Diabetics Type 1 Using InsuPatch
COMPLETED · Phase 3
-
Efficacy of Islet After Kidney Transplantation
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.